Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received androgen receptor pathway inhibition and taxane-based chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000842248.30975.3f | DOI Listing |
Publication Analysis
Top Keywords
metastatic castration-resistant
8
castration-resistant prostate
8
prostate cancer
8
drug metastatic
4
cancer pluvicto
4
pluvicto lutetium
4
lutetium 177
4
177 vipivotide
4
vipivotide tetraxetan
4
tetraxetan approved
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!